This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Dose Response and Safety Study of Topical Methotrexate for the Treatment of Fingernail Psoriasis

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2009 by MediQuest Therapeutics.
Recruitment status was:  Active, not recruiting
Information provided by:
MediQuest Therapeutics Identifier:
First received: April 22, 2008
Last updated: February 9, 2009
Last verified: February 2009
The purpose of this clinical study is to compare the efficacy and safety of three concentrations of topical methotrexate for the treatment of fingernail psoriasis.

Condition Intervention Phase
Fingernail Psoriasis Drug: Methotrexate Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase IIB Dose Response and Safety Study of Topical Formulations of Methotrexate (MQX-5902, MQX-5904 and MQX-5906) in the Treatment of Fingernail Psoriasis

Resource links provided by NLM:

Further study details as provided by MediQuest Therapeutics:

Primary Outcome Measures:
  • Evaluate improvements in the appearance of the target fingernail, utilizing photography for imaging and independent photograph evaluators. [ Time Frame: Monthly ]

Secondary Outcome Measures:
  • Improvement in appearance of the control fingernail, improvement of the target fingernail using mNAPSI (a modification of the Nail Psoriasis Severity Index), and comparison of improvement of mNAPSI of the target and control fingernails. [ Time Frame: Monthly ]
  • Information on the relative changes in nail psoriasis severity of the other affected fingernails will be collected. [ Time Frame: Monthly ]
  • Comparison of nail growth of the target and control fingernails as determined from nail notch movement measured on nail photographs will be performed. [ Time Frame: Monthly ]
  • Assess safety, i.e., the frequency and severity of adverse events associated with MQX-5902, MQX-5904 and MQX-5906 in the treatment of patients with fingernail psoriasis. [ Time Frame: Monthly ]

Estimated Enrollment: 83
Study Start Date: October 2007
Estimated Study Completion Date: January 2009
Estimated Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1 Drug: Methotrexate
0.01 gram of topical amphimatrix containing 0.05% methotrexate per affected nail and adjacent skin folds applied daily for three months.
Other Name: MQX-5906
Active Comparator: 2 Drug: Methotrexate
0.01 gram of topical amphimatrix containing 0.25% methotrexate per affected nail and adjacent skin folds applied daily for three months.
Other Name: MQX-5902
Active Comparator: 3 Drug: Methotrexate
0.01 gram of topical amphimatrix containing 1.0% methotrexate per affected nail and adjacent skin folds applied daily for three months.
Other Name: MQX-5904

Detailed Description:
The purpose of this clinical study is to compare, in a controlled fashion, the response to three concentrations of methotrexate in novel topical formulations in the treatment of subjects with psoriasis of the fingernails. Such a determination will be used as the basis for evidence of efficacy and safety of these formulations as a therapeutic treatment for fingernail psoriasis.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosed moderate fingernail psoriasis of at least two fingernails.
  • Stable and unchanged psoriasis therapies for 2 months and must not have received methotrexate for 3 months prior to screening.
  • Female patients who are not 5 years post menopausal or surgically sterile must use appropriate birth control for specified time periods and have negative pregnancy tests.

Exclusion Criteria:

  • Target or control fingernails that are thicker than 2mm, abnormal or infected (bacterial or fungal).
  • Patients with immunosuppression, HIV, or neuropathies of the hand.
  • Use of any methotrexate preparation, any topical anti-psoriatic medications or ultraviolet treatment within 2 months of study visit 1.
  • Use of more that one 2-week course of oral corticosteroid therapy or one injection during 3 months prior to the screening visit.
  • Use of manicures or cosmetic nail products during and within 7 days of the start of treatment.
  • Use of any drug known to have potential for toxicity to a major organ during and within 90 days prior to the start of treatment.
  • Patients who are nursing, pregnant or plan to become pregnant or father a child within the study time frame including within three months of the last dose of study medication.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00666354

United Kingdom
University of Manchester, The Dermatology Centre
Salford, Manchester, United Kingdom, M6 8HD
Great Western Hospital Rheumatology Department
Swindon, Wiltshire, United Kingdom, SN3 6BB
Aberdeen Royal Infirmary Dermatology Outpatients Clinic
Aberdeen, United Kingdom, AB25 2ZR
Royal National Hospital for Rheumatic Diseases
Bath, United Kingdom, BA1 1RL
University Hospital of Wales, Welsh Institute of Dermatology
Cardiff, United Kingdom, CF14 4XN
Leeds General Infirmary Department of Dermatology
Leeds, United Kingdom, LS1 3EX
George Eliot Hospital, Department of Dermatology
Nuneaton, United Kingdom, CV10 7DJ
Sponsors and Collaborators
MediQuest Therapeutics
Principal Investigator: Prof. Neil McHugh Royal National Hospital for Rheumatic Diseases
  More Information

Responsible Party: Fred Dechow/President and CEO, MediQuest Therapeutics Identifier: NCT00666354     History of Changes
Other Study ID Numbers: 06-003
Study First Received: April 22, 2008
Last Updated: February 9, 2009

Keywords provided by MediQuest Therapeutics:
Nail Psoriasis
Fingernail Psoriasis

Additional relevant MeSH terms:
Skin Diseases, Papulosquamous
Skin Diseases
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunosuppressive Agents
Immunologic Factors
Antirheumatic Agents
Nucleic Acid Synthesis Inhibitors processed this record on September 20, 2017